Daiichi Sankyo Limited

27 days ago · businesswire.com

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimat.

1 month ago · businesswire.com

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization.

1 month ago · businesswire.com

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) has appointed Ken Keller to the newly created role of Chief Commercialization Officer, responsible for accelerating further growth of the company's oncology and specialty medicine business through a new globally integrated Commercialization Unit, effective April 1, 2027. As part of the operational excellence pillar outlined in the new Five-Year Business Plan of Daiichi Sankyo in May 2026, commercialization activities will be centralized and reo.

2 months ago · seekingalpha.com

Daiichi Sankyo Company, Limited (DSNKY) Q1 2027 Earnings Call Transcript

2 months ago · businesswire.com

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026. “Daiichi Sankyo delivered strong revenue growth in the first quarter of fiscal year 2026 as we began execution of our new Five-Year Business Plan,” said Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo. “Three new U.S. approvals for Enhertu and Datroway were received in a single week in May, underscoring the continued strength of our portfolio where.

2 months ago · defenseworld.net

Shuttle Pharmaceuticals (NASDAQ: SHPH - Get Free Report) and Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership. Insider and Institutional Ownership 4.6% of Shuttle Pharmaceuticals

3 months ago · seekingalpha.com

Daiichi Sankyo maintains strong growth prospects, driven by its expanding antibody-drug conjugate (ADC) pipeline and disciplined oncology development. Trastuzumab deruxtecan remains a key growth driver, with ongoing label expansions and pivotal trial readouts expected in 2H 2026 for first-line lung cancer. Datopotamab deruxtecan and raludotatug deruxtecan have secured new approvals and promising data, broadening the company's oncology franchise beyond HER2.